Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk.

Abstract:

:The tumor microenvironment has an essential role in defining tumor malignancy, since it can either promote or prevent tumor initiation and subsequent progression and metastatic dissemination. Recent studies demonstrate that highly aggressive cancer cells display a high degree of metabolic plasticity paralleled by the acquisition of stemness and chemoresistant properties. In addition, cancer-associated fibroblasts, endothelial cells, and immune cells have an important role in shaping the metabolic behavior of cancer cells. This review discusses the current knowledge of metabolic reprogramming in cancer, the tumor-stroma metabolic crosstalk, and the available compounds that may be used to effectively target the tumor-stroma metabolic symbiosis.

journal_name

Trends Cancer

journal_title

Trends in cancer

authors

Morandi A,Giannoni E,Chiarugi P

doi

10.1016/j.trecan.2016.11.001

subject

Has Abstract

pub_date

2016-12-01 00:00:00

pages

736-746

issue

12

eissn

2405-8033

issn

2405-8025

pii

S2405-8033(16)30164-9

journal_volume

2

pub_type

杂志文章,评审
  • Cadherins Glycans in Cancer: Sweet Players in a Bitter Process.

    abstract::Cadherins are key components in tissue morphogenesis and architecture, contributing to the establishment of cohesive cell adhesion. Reduced cellular adhesiveness as a result of cadherin dysfunction is a defining feature of cancer. During tumor development and progression, major changes in the glycan repertoire of canc...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.08.003

    authors: Carvalho S,Reis CA,Pinho SS

    更新日期:2016-09-01 00:00:00

  • The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer.

    abstract::Dysregulation of the PI3K/PTEN pathway is a frequent event in cancer, and PIK3CA and PTEN are the most commonly mutated genes after TP53. PIK3R1 is the predominant regulatory isoform of PI3K. PIK3R2 is an ubiquitous isoform that has been so far overlooked, but data from The Cancer Genome Atlas shows that increased exp...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.02.009

    authors: Vallejo-Díaz J,Chagoyen M,Olazabal-Morán M,González-García A,Carrera AC

    更新日期:2019-04-01 00:00:00

  • Understanding the Cause and Consequence of Tumor Heterogeneity.

    abstract::Tumor heterogeneity is a large conundrum in cancer medicine, making most therapeutic interventions palliative rather than curative. Here we discuss the implications of how molecularly targeted therapies in solid malignancies that promote limited cancer cell death may in fact make tumors more heterogeneous, increase ag...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.01.010

    authors: Khatib S,Pomyen Y,Dang H,Wang XW

    更新日期:2020-04-01 00:00:00

  • Exons of Leukemia Suppressor Genes: Creative Assembly Required.

    abstract::Alternative splicing (AS) has many important roles in the pathogenesis of leukemia. Recent papers suggest that one of its key aspects is exclusion of 3'-terminal exons in favor of premature termination using intronic polyadenylation signals. This process generates leukemia suppressor isoforms with truncated C termini ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.10.005

    authors: Asnani M,Thomas-Tikhonenko A

    更新日期:2018-12-01 00:00:00

  • Thermoneutrality, Mice, and Cancer: A Heated Opinion.

    abstract::The 'mild' cold stress caused by standard sub-thermoneutral housing temperatures used for laboratory mice in research institutes is sufficient to significantly bias conclusions drawn from murine models of several human diseases. We review the data leading to this conclusion, discuss the implications for research and s...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.03.005

    authors: Hylander BL,Repasky EA

    更新日期:2016-04-01 00:00:00

  • ADAR and Immune Silencing in Cancer.

    abstract::The regulation of immune responses by tumors is central to their survival. By diminishing the production of interferon (IFN) and other inflammatory mediators, tumors enhance immune evasion. Responses initiated by nucleic acid sensors and triggered by dysregulated RNA transcription and cytoplasmic DNA undergo down-modu...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.03.004

    authors: Herbert A

    更新日期:2019-05-01 00:00:00

  • Lysophosphatidate Signaling: The Tumor Microenvironment's New Nemesis.

    abstract::Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the tumor microenvironment. Strategies for targeting LPA signaling have recently entered clinical trials for fibrosis. These therapies have potential to improve the efficacies of existing chemotherapies and radiotherapy by attenuating ch...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.09.004

    authors: Benesch MGK,Yang Z,Tang X,Meng G,Brindley DN

    更新日期:2017-11-01 00:00:00

  • Transforming Biomarker Development with Exceptional Responders.

    abstract::Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidatin...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.11.004

    authors: Jonsson P,Taylor BS

    更新日期:2018-01-01 00:00:00

  • Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity.

    abstract::Dynamic changes in the colorectal cancer (CRC) signalome and tumor genetic heterogeneity underlie acquired drug resistance. Improving treatment-related decisions is facilitated by an emerging consensus in the classification of tumor subtypes as well as by real-time monitoring of predictive biomarkers in circulating tu...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.01.003

    authors: Gargalionis AN,Papavassiliou AG

    更新日期:2017-03-01 00:00:00

  • PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy.

    abstract::Targeted therapy has become increasingly important in cancer therapy. For example, targeting the promyelocytic leukemia PML protein in leukemia has proved to be an effective treatment. PML is the core component of super-assembled structures called PML nuclear bodies (NBs). Although this nuclear megaDalton complex was ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.05.005

    authors: Li Y,Ma X,Wu W,Chen Z,Meng G

    更新日期:2020-10-01 00:00:00

  • Emerging role of mTOR in the response to cancer therapeutics.

    abstract::The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to avoid or overcome resistance. T...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2016.03.008

    authors: Ilagan E,Manning BD

    更新日期:2016-05-01 00:00:00

  • Repurposing Drugs in Oncology: Next Steps.

    abstract::The repurposing of existing non-cancer drugs is a potential source of new treatment options for cancer patients with high unmet medical needs. While scientific research is progressing rapidly in the field of drug repurposing, the implementation of drug repurposing still faces important financial and regulatory hurdles...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2017.06.007

    authors: Verbaanderd C,Meheus L,Huys I,Pantziarka P

    更新日期:2017-08-01 00:00:00

  • Exercise Benefits Meet Cancer Immunosurveillance: Implications for Immunotherapy.

    abstract::Regular exercise reduces the risk of cancer. One potential mechanism for this efficacy is improved antitumor immunity. This is an important issue because evading immune destruction is a hallmark of cancer and immunotherapy is reshaping cancer treatment. Here we review recent developments reported by Wennerberg et al.,...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.12.003

    authors: Fiuza-Luces C,Valenzuela PL,Castillo-García A,Lucia A

    更新日期:2021-02-01 00:00:00

  • TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

    abstract::TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.01.007

    authors: Shahbandi A,Nguyen HD,Jackson JG

    更新日期:2020-02-01 00:00:00

  • Exit Stage Left: A Tumor Cell's Journey from Lymph Node to Beyond.

    abstract::Even though we have known for over 250 years that cancers spread to regional lymph nodes (LNs) and distant organs, the fundamental question of which anatomical routes are taken by tumor cells has remained a mystery. Two recently published papers in Science, by Pereira et al. and Brown et al., directly address this imp...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2018.05.007

    authors: Achen MG,Stacker SA

    更新日期:2018-08-01 00:00:00

  • Selective Targeting of RSK Isoforms in Cancer.

    abstract::The p90 ribosomal S6 kinase family (RSK1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. The RSKs phosphorylate a range of substrates involved in transcription, translation, cell cycle regulation, and cell survival. Although the RSKs have a h...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.03.004

    authors: Casalvieri KA,Matheson CJ,Backos DS,Reigan P

    更新日期:2017-04-01 00:00:00

  • Turning Cold into Hot: Firing up the Tumor Microenvironment.

    abstract::Cancers develop within complex tissue environments consisting of diverse innate and adaptive immune cells, along with stromal cells, vascular networks, and many other cellular and noncellular components. The high heterogeneity within the tumor microenvironment (TME) remains a key obstacle in understanding and treating...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.02.022

    authors: Duan Q,Zhang H,Zheng J,Zhang L

    更新日期:2020-07-01 00:00:00

  • Mitochondrial DNA Haplotypes as Genetic Modifiers of Cancer.

    abstract::Mitochondria play an essential role in cellular metabolism, generation of reactive oxygen species (ROS), and the initiation of apoptosis. These properties enable mitochondria to be crucial integrators in the pathways of tumorigenesis. An open question is to what extent variation in the mitochondrial genome (mtDNA) con...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.08.004

    authors: Tasdogan A,McFadden DG,Mishra P

    更新日期:2020-12-01 00:00:00

  • Advanced Prostate Cancer: Treatment Advances and Future Directions.

    abstract::Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.04.010

    authors: Swami U,McFarland TR,Nussenzveig R,Agarwal N

    更新日期:2020-08-01 00:00:00

  • Cancer Genomics in Clinical Context.

    abstract::Precision medicine requires appropriate application of genomics in clinical practice. In cancer, we have witnessed practice-changing examples of how genomic knowledge is translated into more tailored and effective therapies. The next opportunity is to embed cancer genomics in clinical context so that patient-centric l...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2015.07.010

    authors: Chin L,Wargo JA,Spring DJ,Kantarjian H,Futreal PA

    更新日期:2015-09-01 00:00:00

  • Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma.

    abstract::The liver is one of the major metabolic organs in the body, susceptible to injury caused by various factors. In response to injury, sophisticated mechanisms are engaged to repair and regenerate the damaged liver, preventing its failure. When the damage is chronic, regeneration goes awry, impairing liver function and c...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.08.005

    authors: Garrido A,Djouder N

    更新日期:2021-01-01 00:00:00

  • Connecting Timescales in Biology: Can Early Dynamical Measurements Predict Long-Term Outcomes?

    abstract::Prediction of long-term outcomes from short-term measurements remains a fundamental challenge. Quantitative assessment of signaling dynamics, and the resulting transcriptomic and proteomic responses, has yielded fundamental insights into cellular outcomes. However, the utility of these measurements is limited by their...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.12.008

    authors: Tsabar M,Lovitch SB,Jambhekar A,Lahav G

    更新日期:2021-01-12 00:00:00

  • A Molecular Take on Malignant Rhabdoid Tumors.

    abstract::The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic and epigenomic profiling. Distinct mole...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2016.04.003

    authors: Tang M,Verhaak RG

    更新日期:2016-05-01 00:00:00

  • Biophysical Properties of Extracellular Matrix: Linking Obesity and Cancer.

    abstract::Obesity has been associated with increased severity of diagnoses for several types of cancer, and recent evidence suggests that the mechanism by which obese tissues contribute to cancer progression involves the extracellular matrix (ECM). Understanding the physicochemical differences between lean and obese ECM, and ho...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.02.001

    authors: Druso JE,Fischbach C

    更新日期:2018-04-01 00:00:00

  • Microfluidics: A new tool for modeling cancer-immune interactions.

    abstract::In recognition of the enormous potential of immunotherapies against cancer, research into the interactions between tumor and immune cells has accelerated, leading to the recent FDA approval of several drugs that reduce cancer progression. Numerous cellular and molecular interactions have been identified by which immun...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2015.12.003

    authors: Boussommier-Calleja A,Li R,Chen MB,Wong SC,Kamm RD

    更新日期:2016-01-01 00:00:00

  • The Emerging Role of ABL Kinases in Solid Tumors.

    abstract::The Abelson (ABL) tyrosine kinases were identified as drivers of leukemia in mice and humans. Emerging data has shown a role for the ABL family kinases, ABL1 and ABL2, in the progression of several solid tumors. This review will focus on recent reports of the involvement of the ABL kinases in tumor progression using m...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2015.07.004

    authors: Wang J,Pendergast AM

    更新日期:2015-10-01 00:00:00

  • DUBs, Hypoxia, and Cancer.

    abstract::Alterations in protein ubiquitylation and hypoxia are commonly associated with cancer. Ubiquitylation is carried out by three sequentially acting ubiquitylating enzymes and can be opposed by deubiquitinases (DUBs), which have emerged as promising drug targets. Apart from protein localization and activity, ubiquitylati...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.08.005

    authors: Mennerich D,Kubaichuk K,Kietzmann T

    更新日期:2019-10-01 00:00:00

  • A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer.

    abstract::In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.05.014

    authors: Gill J,Cetnar JP,Prasad V

    更新日期:2020-09-01 00:00:00

  • Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer.

    abstract::Immuno-oncology has gained momentum thanks to the success of strategies aimed at enhancing immune-mediated antitumor response. The field of immunotherapeutic transport oncophysics investigates the physical processes that drive cancer immunotherapies. This review discusses three main aspects that determine the outcome ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.11.008

    authors: Nizzero S,Shen H,Ferrari M,Corradetti B

    更新日期:2020-01-01 00:00:00

  • Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers.

    abstract::GLI-similar 1-3 (GLIS1-3), a subfamily of Krüppel-like zinc finger transcription factors, function as key regulators of several biological processes important to oncogenesis, including control of cell proliferation, differentiation, self-renewal, and epithelial-mesenchymal transition. This review provides a short over...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.07.005

    authors: Jetten AM

    更新日期:2019-09-01 00:00:00